Ksilink wishes you all the best for 2022!

Ksilink wishes you all the best for 2022!

What you see here is neither a virtual firework nor has Ksilink become an expressionist. We took this beautiful picture, figuring the AI-based analysis of the pharmacological validation of one of our disease models, to wish you all the best for the coming year. In...
New solutions to treat Rubinstein-Taybi

New solutions to treat Rubinstein-Taybi

Ksilink was happy to welcome the team of Prof. Valérie Mezger-Lallemand from Université Diderot to initiate a collaboration with the aim to establish a new patient-based disease model to identify novel treatment options for patients suffering from Rubinstein-Taybi....
AI-powered Drug Discovery symposium

AI-powered Drug Discovery symposium

We are proud to be present with two posters during the AI powered Drug Discovery Symposium from 8-9th of November 2021 in London, at Francis Crick Institute. Download our poster on myotonic dystrophy type 1 (DM1) here.Download our poster on dilated cardiomyopathies...
Video: Ksilink x 2CRSI

Video: Ksilink x 2CRSI

Ksilink and 2CRSI – acting together to enable next generation medicine. Collaborating since more than 5 years with 2CRSI, Ksilink is honored to be now recognized as one of 2CRSI’s most attractive customers. Find out about how these two highly innovative companies...